Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.

ABSTRACT: Asthma is a heterogeneous respiratory disease characterized by usually reversible bronchial obstruction, which is clinically expressed by different phenotypes driven by complex pathobiological mechanisms (endotypes). In recent years several molecular effectors and signaling pathways have emerged as suitable targets for biological therapies of severe asthma, refractory to standard treatments. Indeed, various therapeutic mono-clonal antibodies currently allow one to intercept at different levels the chain of pathogenic events leading to type 2 (T2) airway inflammation. Pro-allergic immunoglobulin E (IgE) is the first molecule against which an anti-asthma monoclonal antibody (omalizumab) was developed; today other targets are successfully being exploited by biological treatments for severe as

SUBMITTER: Cheng SL 

PROVIDER: S-EPMC8399988 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature